Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow KYMR by emailGet an email when KYMR pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about KYMR, unsubscribe in one click. Privacy
📣 What KYMR Says Is Next
in 2027 · “Gilead intends to progress the program into IND-enabling studies to support an IND filing in 2027.”
Company press release, Aug 5, 2026 · SEC filing
fourth quarter of 2026 · “Enrollment is ongoing in the KT-579 Phase 1 clinical trial in healthy volunteers , with data expected in the fourth quarter of 2026.”
Company press release, Aug 5, 2026 · SEC filing
late 2027 · “The Company expects to report data in late 2027.”
Company press release, Aug 5, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full KYMR picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for KYMR and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.